Prostate Cell News Volume 4.42 | Nov 1 2013

Acquisition of Epithelial-Mesenchymal Transition and Cancer Stem Cell Phenotypes Is Associated with Activation of the PI3K/Akt/mTOR Pathway in Prostate Cancer Radioresistance
Scientists developed three novel prostate cancer (CaP) radioresistant (RR) cell lines by radiation treatment and confirmed their radioresistance using a clonogenic survival assay. Compared with untreated CaP-control cells, the CaP-RR cells had increased colony formation, invasion ability and spheroid formation capability. [Cell Death Dis] Full Article

Panobinostat Synergizes with Zoledronic Acid in Prostate Cancer and Multiple Myeloma Models by Increasing ROS and Modulating Mevalonate and p38-MAPK Pathways
Researchers found a potent synergistic antiproliferative effect of panobinostat/zoledronic acid (ZOL) treatment in three prostate cancer (PCa) and three multiple myeloma cell lines as well as in a PCa ZOL-resistant subline, independently of p53/KRAS status, androgen dependency, or the schedule of administration. [Cell Death Dis] Full Article

Diamide Linked ?-Cyclodextrin Dimers as Molecular-Scale Delivery Systems for the Medicinal Pigment Curcumin to Prostate Cancer Cells
Researchers describe the potential efficacy of N,N’-bis(6A-deoxy-?-cyclodextrin-6A-yl)succinamide (66?CD2su) and N,N’-bis(6A-deoxy-?-cyclodextrin-6A-yl)urea for intracellular curcumin delivery to cancer cells. Cellular viability assays demonstrated a dose-dependent anti-proliferative effect of curcumin in human prostate cancer cells that was preserved by the curcumin-66?CD2su complex. [Mol Pharm] Abstract

Proteomic Signatures of Angiogenesis in Androgen-Independent Prostate Cancer
Scientists interrogated the signaling pathways and the molecular functional signatures across the proteome of endothelial cells after interacting with various secretomes produced by androgen-dependent and -independent prostate cancer cells. [Prostate] Abstract

Aldehyde Dehydrogenase and ATP Binding Cassette Transporter G2 (ABCG2) Functional Assays Isolate Different Populations of Prostate Stem Cells Where ABCG2 Function Selects for Cells with Increased Stem Cell Activity
To test for stem cell characteristics of self-renewal and multipotency, cells with high and low ALDH1A1 activity, based on the ALDEFLUOR^TM assay, were isolated from prostate clinical specimens and were recombined with rat urogenital sinus mesenchyme to induce prostate gland formation. [Stem Cell Res Ther] Abstract | Full Article

PITX2 and Non-Canonical Wnt Pathway Interaction in Metastatic Prostate Cancer
Overexpression of individual PITX2A/B/C isoforms stimulated PC-3 prostate cancer cell motility, with the PITX2A isoform imparting a specific motility advantage in the presence of non-canonical Wnt5a stimulation. [Clin Exp Metastasis ] Abstract

Prostate Transglutaminase (TGase-4, TGaseP) Enhances the Adhesion of Prostate Cancer Cells to Extracellular Matrix, the Potential Role of TGase-Core Domain
Scientists investigated the influence of TGase-4 on cell-matrix adhesion and search for the candidate active domain(s) within the protein. The impact of TGase-4 on in vitro cell-matrix adhesion, cell migration, growth and in vivo growth were investigated. [J Transl Med] Full Article

An Investigation into the Anticancer Effects and Mechanism of Action of Hop ß-Acid Lupulone and Its Natural and Synthetic Derivatives in Prostate Cancer Cells
Scientists investigated the anticancer potency of lupulone and its novel derivatives and their mechanism of action on prostate cancer cells. Screening of natural and new lupulone derivatives for their anticancer activity demonstrated that one displayed stronger anticancer activity than lupulone itself on PC3 and DU145 prostate cancer cells. [Nutr Cancer] Abstract

miR-205 Is Progressively Down-Regulated in Lymph Node Metastasis but Fails as a Prognostic Biomarker in High-Risk Prostate Cancer
Researchers investigated the prognostic potential of microRNA (miR)-205 in high-risk prostate cancer (HRPCa) study and validation cohorts, setting defined clinical endpoints for both. They demonstrated miR-205 to be significantly down-regulated in over 70% of the HRPCa samples analyzed and that reconstitution of miR-205 causes inhibition of proliferation and invasiveness in prostate cancer cell lines. [Int J Mol Sci] Abstract | Full Article

Effect of N-3 and N-6 Unsaturated Fatty Acids on Prostate Cancer (PC-3) and Prostate Epithelial (RWPE-1) Cells In Vitro
Scientists evaluated the effect of various polyunsaturated fatty acids on the proliferation and survival of human prostate cancer and human prostate epithelial cells in vitro. Though all fatty acids tested produced changes in the production of interleukin-6, tumor necrosis factor-alpha, lipoxin A4 and free radical generation by RWPE-1 and PC-3 cells, there were significant differences in their ability to do so. [Lipids Health Dis] Abstract | Full Article

CLINICAL RESEARCH

First-In-Human Phase I Study of EZN-4176, a Locked Nucleic Acid Antisense Oligonucleotide to Exon 4 of the Androgen Receptor mRNA in Patients with Castration-Resistant Prostate Cancer
Investigators evaluated EZN-4176 in men with castration-resistant prostate cancer. Activity of EZN-4176 at the doses and schedules explored was minimal. [Br J Cancer] Abstract

Chemotherapeutic Inhibitors in the Treatment of Prostate Cancer
The authors provide a broad overview of prostate cancer therapeutics and highlights key players in the biology of prostate cancer as well as first- and second-line treatments for castration-resistant prostate cancer. [Expert Opin Pharmacother] Abstract

Visit our REVIEWS page to see a complete list of reviews in the prostate cell research field.

Nutranomics Enters into LOI to Acquire GenEpic™ Prostate Cancer Treatment
Nutranomics, Inc. reported that it has entered into a non-binding Letter of Intent (LOI) with Genesar Nutraceuticals, LLC, with the intent of completing a licensing agreement to market and distribute GenEpic™, a Genesar developed product that is currently undergoing FDA approved human clinical studies. [PR Newswire Association LLC] Press Release

Tokai Pharmaceuticals Announces New Preclinical Data Demonstrating Galeterone Suppresses Resistant Prostate Cancer Growth
Tokai Pharmaceuticals, Inc. announced new preclinical data supporting that its lead candidate, galeterone (TOK- 001) may represent the next-generation of therapy for patients with castration-resistant prostate cancer and disease that has progressed despite treatment with enzalutamide (Xtandi®). [Tokai Pharmaceuticals, Inc.] Press Release

From our sponsor: Learn about assays for cord blood. Download the free technical bulletin.

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the prostate cell community.

NEW Postdoctoral Fellow / Instructor Position – Endocrine Therapies for Cancer (Baylor College of Medicine)

Experienced Researcher Position – Molecular Biology (ServiceXS B.V.)

Postdoctoral Fellow – Mechanisms of DNA Damage in the Development and Progression of Prostate Cancer (Johns Hopkins Hospital)

Senior Postdoctoral Researcher – Signaling and Metabolic Alterations in Prostate and Breast Cancer (CIC bioGUNE)

Research Technician Position – Steroid Receptor Signaling (Baylor College of Medicine)

Postdoctoral Research Associates – Tumor Immune Evasion Mechanism and Inflammation (Hollings Cancer Center)

Postdoctoral Position – Prostate Cancer Biology (University Of Rochester School Of Medicine)

Scientist – Particle Chemistry (STEMCELL Technologies Inc.)

Research Technologist – Human Pluripotent Stem Cell Products (STEMCELL Technologies Inc.)

Research Associate/Scientist – Antibodies Group (STEMCELL Technologies Inc.)

Research Associate – Particle Chemistry (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.